Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis

To assess whether the current body of accumulated data can give convincing evidence in favor of sodium-glucose transport protein-2 inhibitor (SGLT-2i) in all types of heart failure (HF). We searched for randomized controlled trials contrasting the effectiveness of SGLT-2i to placebo or other hypogly...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiehui, Wang, Lili, Li, Huijun, Huang, Weichao, Huang, Siquan, Zhao, Lingyue, Guo, Wenqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755323/
https://www.ncbi.nlm.nih.gov/pubmed/36531703
http://dx.doi.org/10.3389/fcvm.2022.1067806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755323/
https://www.ncbi.nlm.nih.gov/pubmed/36531703
http://dx.doi.org/10.3389/fcvm.2022.1067806

Ejemplares similares